The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer

Table 2

SphK1 and SphK2 inhibitors and their effects in cancer.

SphK inhibitors	Selectivity	Cancer type	References
SKI-1	SphK1	Breast cancer, glioblastoma, leukemia, colon cancer	[3, 28, 99, 141, 146, 147, 152, 154, 186]
K-145	SphK2	Leukemia, breast cancer	[81, 128, 192]
PF-543	SphK1	Breast, colon, and colorectal cancer, leukemia	[62, 91]
ABC294640	SphK2	Liver, breast (ER^+, ER^−), pancreas, bladder, prostate, colorectal, colitis-driven colon, and ovarian cancer, phase I advanced solid tumors, multiple myeloma, cholangiocarcinoma, lung cancer	[62, 83, 193–195]
SKI-II and ABC294735	SphK1 and SphK2	Kidney and pancreatic adenocarcinoma	[66, 70, 92, 196–203]
DMS	SphK1 and SphK2	Breast, lung, and colon cancer, hepatocellular carcinoma, gastric cancer	[204, 205]
SG-12 and SG14	SphK2	Cervical cancer	[62, 206–209]
Safingol	SphK1 and SphK2	Phase I with cisplatin in advanced solid tumors	[65, 210]